Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 296-299

  Elsasser Beile U ^a,b   Gutzeit, O ^a   Bauer, S ^a   Katzenwadel, A ^a   Schultze Seemann, W ^a   Wetterauer, U ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Department of Urology   (Germany)

Author keywords

BCG; Bladder cancer; Leukocyte cytokine; Plasma TNF

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IMMUNOMODULATION; IMMUNOREACTIVITY; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 0344771051     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68041-X     Document Type: Article

References (30)

1. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol, 116: 180, 1976.
2. Lamm, D. L., Thor, D. E., Winters, W. D., Stogdill, V. D. and Radwin, H. M.: BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer, 48: 82, 1981.
3. Haaff, E. O., Catalona, W. J. and Ratliff, T. L.: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol, 136: 970, 1986.
4. Böhle, A., Nowc, C. H., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. and Flad, H.-D.: Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guérin immunotherapy. J Urol, 144: 59, 1990.
5. Bettex-Galland, M., Studer, U. E., Walz, A., Dewald, B. and Baggiolini, M.: Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and Bacillus Calmette-Guérin administration. Eur Urol, 19: 171, 1991.
6. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R., Van der Meijden, A. P. M., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J.: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with Bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother, 34: 306, 1992.
7. De Boer, E. C., De Jong, W. H. D., Van der Meijden, A. P. M., Steerenberg, P. A., Witjes, J. A., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J.: Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with Bacillus Calmette-Guérin. Cancer Immunol Immunother, 33: 411, 1991.
8. Patard, J. J., Muscatelli-Groux, B., Saint, F., Popov, Z., Maille, P., Abbou, C. and Chopin, D.: Evaluation of local immune response after intravesical Bacillus Calmette-Guérin treatment for superficial bladder cancer. Br J Urol, 78: 709, 1996.
9. Elsässer-Beile, V., von Kleist, S. and Gallati, H.: Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Meth, 139: 191, 1991.
10. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Van der Meijden, A. P., Aarden, L. A., Debruyne, F. M. and Ruitenberg, E. J.: Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with Bacillus Calmette-Guérin. In Vivo, 5: 671, 1991.
11. Thalmann, G. N., Dewald, B., Baggiolini, M. and Studer, U. E.: Interleukin-8 expression in the urine after Bacillus Calmette-Guérin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol, 158: 1340, 1997.
12. DeBoer, E. C., Somogyi, L., De Ruiter, G. J., De Reijke, T. M., Kurth, K. H. and Schamhart, D. H.: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res, 25: 31, 1997.
13. Ratliff, T. L., Haaff, E. O. and Catalona, W. J.: Interleukin-2 production during intravesical Bacillus Calmette-Guérin therapy for bladder cancer. Clin Immunol Immunopathol, 40: 375, 1986.
14. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol, 144: 1248, 1990.
15. Jackson, A. M., Alexandrov, A. B., Prescott, S. and James, K.: Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after Bacillus Calmette-Guérin immunotherapy. Cancer Immunol Immunother, 40: 119, 1995.
16. Boccafoschi, C., Montefiore, F., Pavesi, M., Pastormerlo, M. and Betta, P. G.: Late effects of intravesical Bacillus Calmette-Guérin immunotherapy on bladder mucosa infiltrating lymphocytes: an immunohistochemical study. Eur Urol, 27: 334, 1995.
17. Bohle, A., Busemann, E., Gerdes, J., Ulmer, A. J., Flad, H. D. and Jocham, D.: Long-term immunobiological effects of intravesical Bacillus Calmette-Guérin against bladder carcinoma recurrences. Dev Biol Stand, 77: 199, 1992.
18. Sander, B., Damm, O., Gustafsson, B., Andersson, U. and Hakansson, L.: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guérin. J Urol, 156: 536, 1996.
19. Kurisu, H., Matsuyama, H., Ohmoto, Y., Shimabukuro, T. and Naito, K.: Cytokine-mediated antitumor effect of Bacillus Calmette-Guérin on tumor cells in vitro, Cancer Immunol Immunother, 39: 249, 1994.
20. Thanhäuser, A., Böhle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H. D. and Ulmer, A. J.: The induction of Bacillus Calniette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother, 40: 103, 1995.
21. Sarica, K., Baltaci, S., Beduk, Y., Suzer, O., Kilic, S., Muftuglu, Y. Z. and Gogus, O.: Evaluation of cellular immunity following Bacillus Calmette-Guérin therapy in patients with superficial bladder cancer. Urol Int, 54: 137, 1995.
22. Yoshimura, K. and Yamauchi, T.: Influence of intravesical Bacillus Calmette-Guérin therapy on systemic immunological status. Ont J Urol, 4: 456, 1997.
23. van der Meijden, A. P., Steerenberg, P. A., van Hoogstraaten, I. M., Kerckhaert, J. A., Schreinemachers, L. M., Harthoorn-Lasthuizen, E. J., Hagenaars, A. M., de Jong, W. H., Debruijne, F. M. and Ruitenberg, B. J.: Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with Bacillus Calmette-Guérin. Cancer Immunol Immunother, 28: 287, 1989.
24. Hermann, G. G., Petersen, K. R., Zeuthen, J. and Steven, K.: Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells. Scand J Urol Nephrol, 25: 269, 1991.
25. Born, J., Lange, T., Hansen, K., Molle, M. and Fehm, H. L.: Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol, 158: 4454, 1997.
26. Petrovsky, N. and Harrison, L. C.: Diurnal rhythmicity of human cytokine production, a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J Immunol, 158: 5163, 1997.
27. Aderka, D.: The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev, 7: 231, 1996.
28. Zlotta, A., Drowart, A., van Vooren, J. P., Simon, J., Schulman, C. C. and Huygen, K.: Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer. Acta Urol Belg, 62: 63, 1994.
29. Zlotta, A. R., Drowart, A., Huygen, K., de Bruyn, J., Shekarsarai, H., Decock, M., Pirson, M., Jurion, F., Palfliet, K., Denis, O., Mascart, F., Simon, J., Schulman, C. C. and van Vooren, J. P.: Humoral response against heat shock proteins and other myeobacterial antigens after intravesical treatment with Bacillus Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol. 109: 157, 1997.
30. Zlotta, A. R., Drowart, A., van Vooren, J. P., de Cock, M., Pirson, M., Palfliet, K., Jurion, F., Vanonckelen, A., Simon, J., Schulman, C. C. and Huygen, K.: Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of Bacillus Calmette-Guérin during intravesical treatment of superficial bladder cancer. J Urol, 157: 492, 1997.